PR Newswire
CAMBRIDGE, Mass., May 18, 2016
CAMBRIDGE, Mass., May 18, 2016 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that it will present on its extensive oncology pipeline at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, June 3-7, 2016 at McCormick Place, Chicago, Illinois. Final results from a Phase 1 study evaluating the safety, pharmacology and initial efficacy of MM-151 will be presented in a Poster Discussion Session. Merrimack will also present on the results from its Phase 3 NAPOLI-1 study of ONIVYDE®, as well as on multiple therapeutic candidates from its antibody engineering and antibody-directed nanotherapeutic (ADN) technology platforms in six poster sessions.
Poster Discussion Session:
Session Title: Poster Discussion Session, Developmental Therapeutics – Clinical Pharmacology and Experimental Therapeutics
Sunday, June 5, 2016, 11:30 AM - 12:45 PM CT
Location: Arie Crown Theater
Poster Sessions:
Session Title: Gastrointestinal (Noncolorectal) Cancer
Saturday, June 4, 2016, 8:00 AM – 11:30 AM CT
Location: Hall A
Session Title: Gastrointestinal (Noncolorectal) Cancer
Saturday, June 4, 2016, 8:00 AM – 11:30 AM CT
Location: Hall A
Session Title: Gastrointestinal (Colorectal) Cancer
Saturday, June 4, 2016, 8:00 AM – 11:30 AM CT
Location: Hall A
Session Title: Lung Cancer – Non-Small Cell Metastatic
Saturday, June 4, 2016, 8:00 AM – 11:30 AM CT
Location: Hall A
Session Title: Breast Cancer – HER2/ER
Sunday, June 5, 2016, 8:00 AM – 11:30 AM CT
Location: Hall A
Session Title: Tumor Biology
Monday, June 6, 2016, 1:00 PM – 4:30 PM CT
Location: Hall A
About Merrimack
Merrimack is a fully integrated biopharmaceutical company that views cancer as a complex engineering challenge. Through systems biology, which brings together the fields of biology, computing and engineering, Merrimack aims to decrease uncertainty in drug development and clinical validation, and move discovery efforts beyond trial and error. Such an approach has the potential to make individualized treatment of patients a reality. Merrimack's first commercial product, ONIVYDE® (irinotecan liposome injection), was approved by the U.S. FDA in October 2015. With four additional candidates in clinical studies, several in preclinical development and multiple biomarkers designed to support patient selection, Merrimack is building one of the most robust oncology pipelines in the industry. For more information, please visit Merrimack's website at www.merrimack.com or connect on Twitter at @MerrimackPharma.
Forward-Looking Statements
Any statements in this press release about future expectations, plans and prospects for Merrimack constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, as amended. Actual results may differ materially from those indicated by such forward-looking statements. Merrimack anticipates that subsequent events and developments will cause its views to change. However, while Merrimack may elect to update these forward-looking statements at some point in the future, Merrimack specifically disclaims any obligation to do so.
Contacts:
Media Contact
Marianne McMorrow
774-776-1478
[email protected]
Investor Contact
Geoffrey Grande, CFA
617-441-7602
[email protected]
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/merrimack-to-present-on-extensive-oncology-pipeline-at-the-2016-american-society-of-clinical-oncology-annual-meeting-300271184.html
SOURCE Merrimack Pharmaceuticals, Inc.
We use cookies to tailor your experience, measure site performance and present relevant offers and advertisements. By clicking ‘Accept’ or any content on this site, you agree that cookies can be placed on your browser. You can view our privacy policy to learn more.
If you would like to get more data, alerts and access to Real Vision videos, join us as an Insider Tracking Advantage Ultra member